EntroSentry: Pioneering Non-Invasive CRC Detection Worldwide

This project aims to develop the world's first fecal headspace gas detector for colorectal cancer, based on the regulation of metal oxide crystals. By precisely controlling the growth of zinc oxide crystals on the (-1, 0, 0) and (0, 0, 2) planes, we achieve quantitative detection of dual targets: isopropanol and para-cresol, with a clinical accuracy of 99.5%. The cost of a single test is only 500 yuan, significantly lower than the traditional DNA testing cost of 3000 yuan per test.
Our product is designed for various scenarios, including home self-testing, grassroots screening, and hospital-assisted diagnosis, filling a gap in the global early screening market for gas molecules. We aim for a target revenue of 1 million yuan in the first year and plan to expand to 10 million yuan within four years through an OEM model, with a gross profit margin exceeding 58%.
We intend to raise 280 million yuan in three phases to complete medical device registration, iterate products across multiple scenarios, and establish a global presence, capturing a share of China's 20 billion yuan early screening market. Our ultimate goal is to either list on the Sci-Tech Innovation Board or pursue a strategic acquisition exit.